Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
凡德他尼旨在抑制 VEGFR2 和 EGFR 信号传导，但作为复发性卵巢癌的单药疗法，它没有临床疗效，也没有检测到对 VEGFR2 的调节作用
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-09-2308
Annunziata Christina M, Walker Amanda J, Minasian Lori, Yu Minshu, Kotz Herbert, Wood Bradford J, Calvo Katherine, Choyke Peter, Kimm Daniel, Steinberg Seth M, Kohn Elise C
